Journal of Research in Pharmacy Practice

A two-year utilization of the pharmacist-operated drug information center in Iran

Document Type : Original Article

Authors

. Taher Entezari‑Maleki 1
. Mohammad Taraz 2
. Mohammad Reza Javadi 2
. Mir Hamed Hajimiri 2
. Kaeh Eslami 3
. Iman Karimzadeh 4
. Maysam Esmaeili 2
. Kheirollah Gholami 5

1 1 Drug Applied Research Center, Department of Clinical Pharmacy, Shahid Madani Heart Center, Tabriz University of Medical Sciences, Tabriz, Iran Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, Iran Department of Clinical Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 Department of Clinical Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

5 Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, Iran Department of Clinical Pharmacy, Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran

Abstract
Objective: To assess and describe the call services delivered by drug and poison information 
call center (DPIC) of 13‑Aban pharmacy, which is closely operated by the Department of 
Clinical Pharmacy, College of Pharmacy affiliated to Tehran University of Medical Sciences.
Methods: All calls services including counseled and follow‑up calls provided by 13‑Aban 
DPIC to health care professionals and public were collected, documented, and evaluated 
in a 2 years period from July 2010 to June 2012 using the designed software. Data analysis 
was done by SPSS version 16.0.
Findings: Totally 110,310 calls services delivered during a 2 years period. Among 
healthcare professionals, pharmacists, general physicians, and nurses requested more call 
services respectively (P = 0.001). DPIC could detect 585 potential cases of adverse drug 
reactions (ADRs) and 420 cases of major drug‑drug interactions (DDIs).
Conclusion: This study by analyzing and reporting the two-years activities of one of 
the major DPICs in Iran, showed that DPICs can offer drug consultation for healthcare 
professional and public as well as detect and prevent ADRs and DDIs, and therefore can 
promote patients’ health regarding drug therapy.

Keywords

Adverse drug reaction
clinical pharmacy
drug information call center
  drug interaction
Iran
  1. Burkholder D. Some experiences in the establishment and 
    operation of a drug information center. Am J Hosp Pharm 
    1963;20:506‑13.
    2. Beaird SL, Coley RM, Crea KA. Current status of drug 
    information centers. Am J Hosp Pharm 1992;49:103‑6.
    3. Calder G, Davies JS, McNulty H, Smith JC. Drug information 
    network in the United Kingdom National Health Service. Am 
    J Hosp Pharm 1981;38:663‑6.
    4. Maguire ME, D’Arcy PF. Drug information services in 
    four capital cities in the United Kingdom. ‘A tale of four 
    cities’ – London (North East Thames), Cardiff, Belfast, 
    Edinburgh. J Clin Pharm Ther 1988;13:207‑12.
    5. The Council of Europe Expert Group on Safe Medication 
    Practices, Creation of a better medication safety culture in 
    Europe: Building up safe medication practices. Council of 
    Europe; 2007. p. 1‑275. Available from: http://www.coe.int/v 
    t/e/social_cohesion/socsp/Medication%20Safety%20Report.
    pdf. [Last accessed on 2007 May 08].
  2. 6. Markind JE, Stachnik JM. European drug information centers. 
    J Hum Lact 1996;12:239‑42.
    7. Hall V, Gomez C, Fernandez‑Llimos F. Situation of drug 
    information centers and services in Costa Rica. Pharm 
    Pract (Granada) 2006;4:1‑7.
    8. Narhi U. Drug information for consumers and patients review 
    of the research. Publ Nat Agency Med 2006;1:1‑40.
    9. Rosenberg JM, Koumis T, Nathan JP, Cicero LA, McGuire H. 
    Current status of pharmacist‑operated drug information 
    centers in the United States. Am J Health Syst Pharm 
    2004;61:2023‑32.
    10. Rosenberg JM, Schilit S, Nathan JP, Zerilli T, McGuire H. 
    Update on the status of 89 drug information centers in the 
    United States. Am J Health Syst Pharm 2009;66:1718‑22.
    11. Vassilev ZP, Chu AF, Ruck B, Adams EH, Marcus SM. 
    Evaluation of adverse drug reactions reported to a poison 
    control center between 2000 and 2007. Am J Health Syst Pharm 
    2009;66:481‑7.
    12. Angaran DM. Telemedicine and telepharmacy: Current 
    status and future implications. Am J Health Syst Pharm 
    1999;56:1405‑26.
    13. Melnyk PS, Shevchuk YM, Remillard AJ. Impact of the dial 
    access drug information service on patient outcome. Ann 
    Pharmacother 2000;34:585‑92.
    14. Bouvy ML, van Berkel J, de Roos‑Huisman CM, Meijboom RH. 
    Patients’ drug‑information needs: A brief view on questions 
    asked by telephone and on the Internet. Pharm World Sci 
    2002;24:43‑5.
    15. Hands D, Stephens M, Brown D. A systematic review of the 
    clinical and economic impact of drug information services on 
    patient outcome. Pharm World Sci 2002;24:132‑8.
    16. Rosenberg JM, Fuentes RJ, Starr CH, Kirschenbaum HL, 
    McGuire H. Pharmacist‑operated drug information centers 
    in the United States. Am J Health Syst Pharm 1995;52:991‑6.
    17. Müllerová H, Vlcek J. European drug information 
    centres – Survey of activities. Pharm World Sci 1998;20:131‑5.
    18. Malone PM, Kier KL, Stanovich JE. Drug Information: 
    A Guide for Pharmacists. 3th ed. New York: The McGraw‑Hill 
    Companies; 2007.
    19. Shadnia S, Soltaninejad K, Sohrabi F, Rezvani M, Barari B, 
    Abdollahi M. The performance of Loghman‑Hakim drug and 
    poison information center from 2006 to 2008. Iran J Pharm Res 
    2011;10:647‑52.
    20. Timpe EM, Motl SE. Frequency and complexity of queries to 
    an academic drug information center, 1995‑2004. Am J Health 
    Syst Pharm 2005;62:2511‑4.
    21. Saskatchewan Drug Information Service Annual Report 
    April 1, 2009 – March 31, 2010. College of Pharmacy and 
    Nutrition, University of Saskatchewan 110 Science Place, 
    Saskatoon SK S7N 5C9. Available from: http://medsask.usask. 
    ca/documents/annual-reports/2009-2010_SDIS_Annual_ 
    Report.pdf. [Last accessed date 2014 June].
    22. Pohjanoksa‑Mäntylä MK, Antila J, Eerikäinen S, Enäkoski M, 
    Hannuksela O, Pietilä K, et al. Utilization of a community 
    pharmacy‑operated national drug information call center in 
    Finland. Res Social Adm Pharm 2008;4:144‑52.
    23. Churi S, Abraham L, Ramesh M, Narahari MG. Evaluation 
    of poison information services provided by a new poison 
    information center. Indian J Pharmacol 2013;45:496‑501.
    24. de Sousa IC, de Lima David JP, Noblat Lde A. A drug 
    information center module to train pharmacy students in 
    evidence‑based practice. Am J Pharm Educ 2013;77:80.
    25. Sarkar U, Handley MA, Gupta R, Tang A, Murphy E, 
    Seligman HK, et al. Use of an interactive, telephone‑based 
    self‑management support program to identify adverse events 
    among ambulatory diabetes patients. J Gen Intern Med 
    2008;23:459‑65.
    26. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse 
    drug reactions in hospitalized patients: A meta‑analysis of 
    prospective studies. JAMA 1998;279:1200‑5.
    27. Kavitha D. Adverse drug reaction (ADR) monitoring and 
    pharmacovigilance. J Pharm Res Health Care 2010;2:127‑34.
    28. Ann. Guidance for Industry – Good Pharmacovigilance 
    Practices and Pharmacoepidemiologic Assessment. 2005. US 
    Food and Drug Administration. Available from: http://www.
    fda.gov/downloads/Regulatory Information/Guidances/
    UCM126834.pdf. [Last accessed on 2010 Mar 01].
    29. Riedl MA, Casillas AM. Adverse drug reactions: Types and 
    treatment options. Am Fam Physician 2003;68:1781‑90.
    30. Oberg KC. Adverse drug reactions. Am J Pharm Educ 
    1999;63:199‑204.
    31. Moura CS, Acurcio FA, Belo NO. Drug‑drug interactions 
    associated with length of stay and cost of hospitalization. 
    J Pharm Pharm Sci 2009;12:266‑72.
    32. Moura C, Prado N, Acurcio F. Potential drug‑drug 
    interactions associated with prolonged stays in the intensive 
    care unit: A retrospective cohort study. Clin Drug Investig 
    2011;31:309‑16.
    33. Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T. Fatal 
    adverse drug events: The paradox of drug treatment. J Intern 
    Med 2001;250:327‑41.
Journal of Research in Pharmacy Practice
Volume 3, Issue 4
Autumn 2014
Pages 116-122

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us